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Context: Short stature has an incidence of three in 100 in children. Reliable molecular genetic
testing may be crucial in the context of beneficial disease management. Deletions spanning or
surrounding the SHOX gene account for a significant proportion of patients with idiopathic short
stature (ISS) and allied disorders, such as Leri-Weill dyschondrosteosis.
Objective: Several shortcomings of current strategies for copy number profiling of the SHOX
region prompted us to develop an improved test for molecular diagnostics of the SHOX region.
Design andResults:We introduced a quantitative PCR (qPCR)-based copy number profiling test,
consisting of 11 amplicons targeting clinically relevant regions, i.e. the SHOX gene and reg-
ulatory regions. To ensure an optimal sensitivity and specificity, this test was validated in 32
controls and 18 probands with previously identified copy number changes. In addition, 152
probands with SHOX-associated phenotypes were screened, revealing 10 novel copy number
changes.
Conclusion: This highly validated qPCR test supersedes other approaches for copy number screen-
ing of the SHOX region in terms of reliability, accuracy, and cost efficiency. In addition, another
strong point is the fact that it can be easily implemented in any standard equipped molecular
laboratory. Our qPCR-based test is highly recommended for molecular diagnostics of idiopathic
short stature and allied disorders. (J Clin Endocrinol Metab 95: 0000–0000, 2010)
Short stature,withan incidenceof three in100 inchildren,may have a significant impact on the quality of life.
Patients not only experience physical burdens but also have
tocopewith social, educational, andprofessional impact (1).
The latter highlights the need for a multidisciplinary ap-
proach for these patients, including reliable molecular ge-
netic testing.
Deletions spanning or surrounding the SHOX gene
account for a significant proportion of patients with
idiopathic short stature (ISS) and allied disorders, such
as Leri-Weill dyschondrosteosis (LWD). Recently, it has
been shown that patients with a molecular defect of
SHOX benefit from GH therapy (2, 3). An early mo-
lecular diagnosis is essential for GH therapy because
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there is a time-sensitive window for treatment. In ad-
dition, it is expensive and time-consuming and implies
medicalization. In light of this, an efficient diagnostic
screening method to detect copy number changes span-
ning SHOX and/or the surrounding pseudoautosomal
region 1 (PAR1) is thus of utmost importance.
The PAR1on the distal end of theX andY chromosomes
spans approximately 2.7 Mb and is characterized by an ex-
traordinarily high recombination frequency. The 24 known
geneswithin this region escapeX-inactivation, and their
inheritance mimics an autosomal dominant inheritance
pattern, referred to as pseudoautosomal inheritance (4).
The short stature homeobox-containing gene (SHOX),
encoding a transcription factor, represents the single
known disease gene within the PAR1. Functional loss of
SHOX has been associated with a reduced body height in
different clinical entities, including ISS (OMIM300582),
LWD (OMIM127300), and Langer mesomelic dyspla-
sia (OMIM249700) (5–7). Haploinsufficiency of SHOX
due to heterozygous intragenic mutations, total gene
deletions, or microdeletions downstream of the tran-
scription unit, accounts for at least 5% of the cases with
ISS and for 50–100% of the cases with LWD depending
on the cohort studied (8–11). Interestingly, deletions
account for the major proportion of identified defects
(10, 12). Several techniques have been applied to iden-
tify these abundant deletions, including fluorescence in
situ hybridization, microsatellite analysis, quantitative
PCR (qPCR) with amplicons restricted to the SHOX
gene and more recently multiplex ligation-dependent
probe amplification (MLPA) (10, 13–16). Fluorescence
in situ hybridization analysis for the SHOX region has
been used in a routine setting for many years but re-
quires metaphase or interphase chromosomes and is
limited in resolution. Microsatellite and single-nucle-
otide polymorphism analysis with a confined set of
markers has been shown to be an effective alternative,
but the major disadvantage is the need for parental
DNA (14). MLPA overcomes this and has been dem-
onstrated to be a sensitive and cost-effective alternative;
however, these regularly changing probe mixes are in-
tended for research purposes, requiring extensive in-
house validation after each small modification of the
MLPAprobemix (16, 17). Other drawbacks include the
need for highly purified DNA, the long ligation step,
and themultiple post-PCR handling steps. To overcome
these shortcomings, we designed and validated an in-
house developed qPCR test for SHOX and its surround-
ing 5 and 3 regulatory regions. We demonstrate that
our new test is an appealing strategy for the identifica-
tion of genomic rearrangements in the SHOX region in
patients with ISS, LWD, or other phenotypes.
Patients and Methods
Patient samples
Overall, 213 consenting probandswere enrolled in this study.
Thecohort consistedof207diagnostic referrals for ISS (e.g. short
stature with unknown etiology) derived predominantly from pe-
diatric endocrinology clinics during the period 2005–2008. Stat-
ure was recorded and SD scores were determined according to a
matched population for age and gender. Inclusion criteria for
LWDwere presence ofMadelung deformity and shortening of the
limbs in the proband or a direct family member. In addition, six
patients with other clinical indications were referred to our labo-
ratory to confirm copy number changes in the PAR1, which were
initially detected using other techniques such as subtelomeric
MLPA. The study was conducted following the tenets of Helsinki.
GenomicDNA (gDNA)was purified fromEDTAblood sam-
ples (1–10 ml) using the Gentra Systems (Minneapolis, MN)
Puregene DNA purification method and subsequently stored at
4 C. DNA concentration and purity (A260/A280) were assessed
usingaNanodropND-1000 (ThermoScientific,Waltham,MA).
MLPA
From 2005 to 2007,MLPAwas performed for 115 probands
as described in the protocol providedby themanufacturer (MRC
Holland, Amsterdam, The Netherlands). During this period,
three generations of MLPA mixes for the SHOX region were
released (P018, P018B, and P018C; MRC Holland). Each iden-
tified copy number change was confirmed by repeating the
MLPA analysis. In the context of validation, 72 of 115 MLPA-
prescreened samples were subsequently analyzed using our
newly developed qPCR test. The remaining 43 MLPA-screened
samples were not analyzed with qPCR.
All copy number changes newly identified using our qPCR
test were confirmed using the MLPA mix P018D.
qPCR
Apartof thehumanPAR1sequence (chrX:1–1,000,000)was
retrieved from theUCSCGenomebrowser (HumanMarch2006
Assembly, hg18). A dedicated selection of qPCR assays (ampli-
cons) was based upon 1) the coding region of SHOX and 2) the
shortest region of overlap (SRO) of previously reported regula-
tory deletions 3 to SHOX. Subsequently, a comparison was
made with the location of the MLPA probes. Thirteen qPCR
primer pairs were designed according to guidelines described
previously (18) using PrimerQuest (Integrated DNA Technolo-
gies, Coralville, IA). The BLAST program from the NCBI
browser (http://www.ncbi.nlm.nih.gov/BLAST) was used for
in silico specificity analysis (primer sequences submitted in
RTPrimerDB; primer IDs in Table 1). Subsequently, single-nu-
cleotide polymorphisms and copy number polymorphisms were
excluded at the annealing sites using the corresponding tracks
from the UCSC browser (http://genome.ucsc.edu). In addition,
the absence of secondary structures in the region in which the
primers anneal was verified using MFOLD (http://frontend.
bioinfo.rpi.edu/applications/mfold/cgi-bin/dna-form1.cgi) (19).
Primers were synthesized without special purification (Biolegio,
Nijmegen, The Netherlands). The in silico validation was fol-
lowed by an extensive empirical validation. First, amplification
efficiencies were calculated based upon the generation of stan-
dard curves using gDNA dilution series. Assays with amplifica-
tion efficiencies between 85 and 115% were considered as ac-
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ceptable (Table 1). The specificity of each amplicon was tested
based upon melting curve analysis and microchip electrophore-
sis, using theDNA-500 kit (MultiNA; Shimadzu, Kyoto, Japan).
qPCR was carried out in white 384-well plates (Roche, Basel,
Switzerland) using the qPCR Core kit for SYBR Green I (Euro-
gentec, Seraing, Belgium) on the LightCycler 480 (Roche). The
final volume of 7.5 l contained 0.375 l of each primer (work-
ing solution 5 M), 3.75 l master mix, and 10 ng gDNA. Each
PCR was carried out in duplicate with the following cycling
conditions: 10 min at 95 C; 40 cycles of 15 sec at 95 C, 45 sec at
60C, and1 sec at 72C; and finally adissociation run from60–95
C (melting curve analysis). Quantification cycle values were ex-
tracted with the Lightcycler 480 software (version 1.5.0 SP3)
using the second-derivative maximum algorithm. qBasePlus
software (Biogazelle, Ghent, Belgium) was used for quality con-
trol and calculation of relative quantities using ZNF80 and
GPR15 for normalization (20). Samples that did not pass quality
control because of excessive variance between replicates (0.5
cycle) were excluded from further analysis (21). Next, the nor-
malized relative quantities (NRQs) were exported to Excel and
transformed using a rescaling factor based on reference samples
with known copy number. Where possible, the rescaling factor
was calculated frommultiple reference samples, e.g. two normal
control samples and a sample with a known deletion.
Screening of 32 normal control samples was performed to
assess the normal variation. The mean and the SD of the log2-
transformed NRQs were calculated for each amplicon. These
values were subsequently used to deduce amplicon-specific con-
fidence intervals for samples with a normal copy, with a het-
erozygous deletion, and with a heterozygous duplication.
The qPCR assays were successfully performed either using an
automated laboratory liquid handling system (Freedom Evo 75;
Tecan, Ma¨nnedorf, Switzerland) or by manual pipetting for 170
probands. Ingeneral,onemanuallyperformedrunconsistedofnine
samples of interest, three reference samples, and one no-template
control. Complete runs or single samples that did not pass quality
controlwere repeated.Theoptimal cutoff values todefinedeletions
and duplications, without generating false negatives or many false
positives, were assessed. First, amplicon-specific 95% confidence
intervals were deduced for samples with a normal copy log2(2)
2.04 SD,with a heterozygous deletion log2(1)2.04 SD, and
with a heterozygous duplication log2(3)  2.04  SD. Subse-
quently, cutoff values based upon the generated confidence inter-
vals were evaluated (similar to array comparative genomic hybrid-
ization and MLPA). Each identified copy number change was
confirmed by repeating the qPCR analysis.
AnRDML file of the entire studywas created using qBasePlus
(available upon request) (22).
This study is written according to theMinimum Information
for Publication of Quantitative Real-Time PCR Experiments
guidelines to ensure its technical qualities and toallow for correct
interpretation and repeatability (23). A checklist is available
(Supplemental data published on The Endocrine Society’s Jour-
nals Online web site at http://jcem.endojournals.org).
Results
In this study, we developed a qPCR-based molecular test
consisting of 11 assays. Our main criterion for the design
consisted of the capacity to identify clinically relevant
copynumber changesof thePAR1,more specifically of the
SHOX coding region and the SRO of previously reported
regulatory deletions 3 to SHOX.
MLPA data used for method comparison
From 2005–2007, MLPA was successfully applied for
copynumberscreeningofSHOXandthedownstreamPAR1
in 115 probands using different probe mixes P018, P018B,
and P018C (Fig. 1). The description of these MLPA data is
added for the method comparison of the qPCR data.
MLPA using the P018 probe mix was used in 44 pro-
bands, revealing seven heterozygous deletions of the SHOX
gene and one heterozygous deletion downstream of SHOX.
In addition, two heterozygous duplications of SHOX were
found, oneofwhichwas identified in apatientwith a clinical
diagnosis of ISS. This first-generationMLPAmix comprised
onlya fewprobesdownstreamofSHOX (Fig. 1),whichmay
have hampered the identification of deletions outside the
SHOX coding region. To overcome this, additional probes
wereaddedby themanufacturer, resulting in the secondgen-
eration probemix P018B. Indeed, reanalysis of nine patients
initially screened with P018 led to the identification of one
new extragenic deletion. Forty-nine new probands were an-
alyzed using P018B, revealing three new deletions. Two of
three deletions comprised SHOX, whereas one deletionwas
located downstream of SHOX. For the region downstream
of SHOX, only copy number changes spanning several
probes were regarded as true positive mainly because of the
presence of less reliable probes as indicated by themanufac-
turer. Later on, some of these unreliable probes were ex-
cluded from themix, resulting in the P018C probemix. The
MLPA P018C probe mix consisted of eight probes for the
SHOX coding region, two for the region5 toSHOXand12
for the region 3 to SHOX. Four patients prescreened with
P018 and/or P018B were reanalyzed, and 22 new probands
were screened. The included extragenic deletion was identi-
fied, and one new SHOX duplication was detected.
In-house developed qPCR-based molecular test
Elevenof the13 in silico validatedqPCRprimerpairsmet
our quality control criteria based upon the generation of
standard curves using gDNA dilution series and microchip
electrophoresis (Fig. 2 andTable 1).Amplicons3 and9were
excluded due to inefficient amplification and nonspecific
PCR products, respectively. To explore the normal copy
numbervariabilityof remainingamplicons, theqPCRassays
were performed on 32 normal control samples. Four in-
cludedno-template control samples passed for all 11 targets,
and the reference target stability value was high (M 0.5).
Each PCRampliconwas analyzed separately, and nine sam-
ple-target combinations that did not pass quality control be-
cause of excessive variance between replicates (0.5 cycle)
were excluded from the analysis. No copy number changes
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FIG. 1. Human Genome Browser view of the SHOX region. The SHOX region (chrX: 0–1,000,000) with custom tracks showing the MLPA probes
(P018, P018C, and P018D), the qPCR amplicons used in the study, the SRO described by Benito-Sanz et al. (14), the SRO reported by Fukami et al.
(26), and the location of an 824-bp evolutionarily conserved element described by Fukami et al. (27). The horizontal bars represent the different
copy number changes identified by qPCR. Locations and sizes of the deletions/duplications based upon qPCR results are indicated by horizontal
red/green bars, respectively. The red/dark green bars indicate the minimal deleted/duplicated regions, and the pink/light green bars indicate the
regions harboring the breakpoints. The extent of the copy number changes represented in this figure is based upon the qPCR results for the
different samples. However, it is important to notice that all copy number changes were confirmed using MLPA (different mixes). The numbers
correspond with the patient codes used in the RDML files. In addition, the RefSeq Genes track and the Vertebrate Multiz Alignment and PhastCons
Conservation (28 Species) track are included. The location of the SHOX gene is marked by the blue rectangle. The figure was drawn according to
the UCSC Human Genome Browser, March 2006.
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FIG. 2. Validation of 13 in silico-designed primer pairs. A, Standard curves for each of the 13 in silico-designed amplicons generated using gDNA
dilution series. Failing replicates (0.5 cycle difference) were excluded. The standard curves were extracted from qBasePlus (Biogazelle). All
amplification efficiencies are more than 85%, except for amplicon 3. Cq, Quantification cycle. B, Results from microchip electrophoresis (MultiNA;
Shimadzu). Shown from left to right areDNA-500 ladder, amplicons 1–13, ZNF80, and GPR15. All bands correspond with the correct size, except
for amplicon 9 that shows two bands.
6 D’haene et al. Copy Number Profiling of the SHOX Region J Clin Endocrinol Metab, June 2010, 95(6):0000–0000
were detected in the control samples. Themean and SD of the
log2-transformed NRQs was calculated for each amplicon.
These values were subsequently used to deduce amplicon-
specific 95% confidence intervals (Table 2). The confidence
intervals for duplications and normal alleles show overlap
for only two qPCR assays (i.e. amplicons 8 and 12). In gen-
eral, duplications are more difficult to detect than deletions,
because their ratio (3:2) is closer to the normal ratio (2:2).
Therefore, an upper cutoff value of 1.29 was chosen, and
duplicationswereregardedastruepositivesonly ifmorethan
one adjacent qPCR assay showed values above 1.29. Con-
fidence intervals fordeletionsandnormalallelesdonotover-
lap. Based upon the 95% confidence intervals, 0.5 was cho-
sen as the lower cutoff value.
Overall, reliableqPCRresultswereobtained for170sam-
ples from unrelated patients, including 18 samples with
knowncopynumberchanges (14fromourMLPAscreenings
and four subtelomere-positivepatients), 58negative samples
previously screened by means of MLPA, and 94 new sam-
ples. The reasons for including 18 samples with a known
copy number change (deletions and duplications) in the
PAR1 were 3-fold: 1) to evaluate the cutoff values, 2) to
assessthesensitivityoftheqPCR-basedtest,and3)tostream-
line the results generated using MLPA with different probe
mixes (Fig. 1). All known copy number changes could be
detected using the defined cutoff values, indicating a high
sensitivity of the test. In addition, it was used to analyze 58
samples forwhichMLPAscreeningwasnegative, resulting in
the detection of one new deletion downstream of SHOX
(sample 8 in Fig. 1). The latter can be explained by the fact
that this sample was screened with the first-generation
MLPAmix (P018) not containingprobes in the downstream
regulatory region. However, we were able to demonstrate
that the recent P018D MLPA mix also allows the identifi-
cation of this deletion. In addition, 94 new samples were
screened, revealing nine new copy number changes, includ-
ingeightSHOXdeletions(samples1,7,9,10,11,95,97,and
94) and one regulatory deletion (sample 194 in Fig. 1). All
newly identified copynumber changeswere confirmedusing
the P018DMLPA mix.
Phenotypic information of the mutation-positive
patients
Of 213 probands, 207 were initially referred for mo-
lecular diagnosis of ISS. Reinspection of the clinical
records after the identification of a copy number change in
the PAR1 (17 SHOX deletions, one SHOX duplication,
and five regulatory deletions) revealed that 15 were diag-
nosed with LWD and that six were diagnosed with ISS. In
addition, twopatients appeared tohaveTurner syndrome.
Apart from the latter group, six patients were referred to
our laboratory for screening in the context of other clinical TA
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indications to confirm duplications in the PAR1, previously
found using subtelomericMLPA. This group included three
patientswithSHOXduplicationsassociatedwithcongenital
anomalies, more specifically gastrointestinal malformations
(de Jong, E. M., T.-S. Barakat, B. H. Eussen, B. D’haene, E.
De Baere, P. P. Poddighe, R.-J. Galjaard, J. Gribnau, A. S.
Brooks, D. Tibboel, and A. de Klein in preparation). The
three other patients presented (mild) mental retardation.
Therewere no specific growth abnormalities reported in any
of these six patients carrying SHOX duplications.
Discussion
MLPAwith a commercially availablemix has been shown
to be instrumental for detecting copy number changes of
the SHOX region, but we experienced the disadvantages
of thorough in-house validation after each small adapta-
tion to the probemix. To overcome these and other short-
comings, we aimed to set up a robust and extensively val-
idated molecular genetic test for ISS and LWD. We
developed a qPCR-based test with 11 in silico and empir-
ically validated amplicons located in the SHOX coding
region and in the SRO of previously identified PAR1 de-
letions downstream of SHOX. Unlike the previously re-
ported qPCR test for the SHOX coding region (13), our
assays underwent dedicated design and validation de-
scribed in detail here. The qPCR test presented byTan and
Loke (13) contained only targets for the SHOX gene itself
and was validated on only nine patient samples and 12
controls. For our study, we followed theMinimum Infor-
mation for Publication of Quantitative Real-Time PCR
Experiments (MIQE) guidelines to ensure the relevance,
accuracy, correct interpretation, and repeatability of our
method (23). We screened 115 patients for copy number
variations of the SHOX region using MLPA, resulting in
the identification of a heterozygous copy number change
in 15 probands, including nine SHOX deletions, three
SHOXduplications, and threedownstreamregulatoryde-
letions. Seventy-two of the 115 samples screened by dif-
ferent MLPA mixes were analyzed with our newly devel-
oped automated qPCR-based molecular genetic test. In
addition, we analyzed four samples positive for subtemo-
leric MLPA screening. All included copy number changes
previously identified byMLPAwere also detectedwith the
qPCR assay, demonstrating its sensitivity. In addition, we
identified one new deletion downstream of SHOX that
was missed by MLPA mix P018. Subsequently, this dele-
tion could be confirmed with the P018D probe mix. Since
the implementation of our novel test, we screened 94 new
patients revealing eight SHOX deletions and one regula-
tory deletion. Although our molecular genetic test targets
fewer regions than the MLPA probe mixes, it proved to
reveal all copy number changes previously identified using
MLPA, thusmeeting our criteria. This can be explained by
the dedicated selection of the targets based upon clinical
relevance and by the validated primer pairs. We can con-
clude that our qPCR test is an appealing alternative to
MLPAfor the identificationof copynumber changes in the
SHOX and downstream regulatory region.
Previously, it was suggested that SHOX gene duplica-
tions might be responsible for overgrowth (24). Recently,
two studies were published reporting patients with het-
erozygous SHOX duplications (25, 26). The effect of the
identified duplications appeared to be variable, with only
a slightly elevated height in some patients. Here, we found
a SHOXduplication in at least one patient diagnosedwith
ISS. Furthermore, other duplications were found in pa-
tients with clinical diagnoses other than ISS or LWD, in
whom SHOX testing was requested to confirm a dupli-
cation previously identified by subtelomeric MLPA (de
Jong, E.M., T.-S. Barakat, B.H. Eussen, B.D’haene, E.De
Baere, P. P. Poddighe, R.-J. Galjaard, J. Gribnau, A. S.
Brooks, D. Tibboel, and A. de Klein, in preparation).
High-density oligonucleotide arrays or array compar-
ative genomic hybridizationmight be regarded as another
alternative to MLPA and qPCR, but the high GC content
of the PAR1 and the abundance of Alu repeats leading to
an extremely high recombination rate hamper the design
of targeted arrays for this region. Moreover, these arrays
are still relatively expensive and require more hands-on
time. It should be noted that the most recent array tech-
nologies possess an extremely high resolution (up to a few
base pairs) either for a targeted region or genome wide,
whereas the resolutionaqPCRtest dependson thenumber
of assays and their location. A higher resolution requires
additional amplicons and hence additional reactions.
Therefore, a higher resolution will result in higher con-
sumable costs. In general, qPCR is not convenient for ge-
nome-wide applications, in contrast to microarray-based
copy number screening. Interestingly, advantages of our
qPCR test are the short hands-on time and low average
costs: pipetting, PCR, and data analysis takes less than 4 h
for nine patients, and the cost per sample is relatively low,
facilitating its implementation as a molecular genetic test.
Without taking into account staffing and equipment costs,
we calculated that our qPCR assays costs approximately
11 Euros per sample, whereasMLPA costs approximately
19 Euros per sample. We did not take into account per-
sonnel costs because these are similar for both techniques,
and although equipment costs have not been taken into
account, it shouldbenoted that these aremore expensive for
MLPA (thermocycler, capillary electrophoresis analyzer,
type ABI3730XL or ABI3130) than for qPCR (Lightcycler;
Roche). Moreover, it can be fully automated using a liquid
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handling system and, if required, new amplicons can be eas-
ily addedwithout the need for additional validation of the
existing amplicons, demonstrating its flexibility. In con-
clusion, our novel molecular test is a reliable and cheap
alternative strategy for the identification of copy number
changes in the SHOX region in patients with ISS, LWD,
and allied phenotypes. It can be applied both in a research
as well as in a routine setting, which is highly relevant
because the incidence of SHOX rearrangements is high
and because a correct clinical and molecular diagnosis of
growth retardation is important with respect to proper
management and beneficial therapy.
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